Dr. Dirk Huebner M.D. serves as Chief Medical Officer of the Company. Previously, from August 2017 to November 2018, Dr. Huebner served as Vice President, Head of Development, for Boston Biomedical. Prior to that, he spent six years at Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda focused on oncology, as Executive Medical Director. Prior to that, he held roles of increasing leadership and responsibility in global clinical drug development at Genzyme, Roche, and Bristol-Myers Squibb..
As the Chief Medical Officer of Mersana Therapeutics Inc, the total compensation of Dirk Huebner at Mersana Therapeutics Inc is $1,147,800. There are 1 executives at Mersana Therapeutics Inc getting paid more, with Anna Protopapas having the highest compensation of $1,739,800.
Dirk Huebner is 57, he's been the Chief Medical Officer of Mersana Therapeutics Inc since 2018. There are 5 older and 12 younger executives at Mersana Therapeutics Inc. The oldest executive at Mersana Therapeutics Inc is Lawrence Alleva, 70, who is the Independent Director.
Dirk's mailing address filed with the SEC is C/O MERSANA THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Mersana Therapeutics Inc have traded over $1,068,087 worth of Mersana Therapeutics Inc stock and bought 26,457,775 units worth $226,822,416 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Mersana Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $534,621. The most recent stock trade was executed by Anna Protopapas on 13 January 2024, trading 86,958 units of MRSN stock currently worth $153,916.
mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.
Mersana Therapeutics Inc executives and other stock owners filed with the SEC include: